Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, JUNE 2, 2026

The board of directors (the "**Board**") of InSilico Medicine Cayman TopCo (the "**Company**") is pleased to announce that the annual general meeting of the Company (the "**AGM**") held by way of electronic meeting on Tuesday, June 2, 2026, all the proposed resolutions as set out in the notice of the AGM were taken by poll. Unless otherwise specified, the terms used in this announcement should have the same meanings as those defined in the circular of the Company dated 28 April 2026 (the "**Circular**"). The poll results are as follows:

Ordinary Resolutions*		**Number of Votes (Approximate %)**	
		For	**Against**
1.	To consider, receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended December 31, 2025.	227,916,617 (100.00%)	0 (0.00%)
2(a).	To re-elect Mr. Aleksandrs Zavoronkovs, Ph.D. as an executive director of the Company.	220,253,613 (97.15%)	6,463,004 (2.85%)
2(b).	To re-elect Mr. Feng Ren, Ph.D. as an executive director of the Company.	223,351,890 (98.52%)	3,364,727 (1.48%)
2(c).	To re-elect Ms. Denitsa Milanova, Ph.D. as an independent non-executive director of the Company.	225,628,719 (99.52%)	1,087,898 (0.48%)
2(d).	To re-elect Mr. Jingsong Wang, Ph.D. as an independent non-executive director of the Company.	224,782,903 (99.15%)	1,933,714 (0.85%)

Ordinary Resolutions*		Number of Votes (Approximate %)	
		For	Against
2(e).	To re-elect Mr. Roman Kyrychynskyi as an independent non-executive director of the Company.	225,628,719 (99.52%)	1,087,898 (0.48%)
2(f).	To authorize the board of directors of the Company to fix the respective directors' remuneration.	224,699,886 (99.11%)	2,016,731 (0.89%)
3.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and to authorize the board of directors of the Company to fix auditor's remuneration.	214,446,314 (94.09%)	13,470,303 (5.91%)
4.	To give a general mandate to the directors of the Company to purchase the Company's shares not exceeding 10% of the total number of issued shares (excluding treasury shares, if any) of the Company as at the date of passing of this resolution (the "**Repurchase Mandate**").	227,916,614 (100.00%)	0 (0.00%)
5.	To give a general mandate to the directors of the Company to issue, allot and deal with additional shares (including any sale or transfer of treasury shares held under the name of the Company, if any) of the Company not exceeding 20% of the total number of issued shares (excluding treasury shares, if any) of the Company as at the date of passing of this resolution (the "**Issue Mandate**").	200,844,857 (88.12%)	27,071,757 (11.88%)
6.	Conditional upon the passing of resolutions nos. 4 and 5, to extend the Issue Mandate granted to the directors of the Company to issue, allot and deal with additional shares in the capital of the Company (including any sale or transfer of treasury shares held under the name of the Company, if any) by the aggregate number of shares repurchased by the Company under the Repurchase Mandate.	194,065,017 (85.15%)	33,851,597 (14.85%)

* The full text of the resolutions was set out in the notice of AGM.

Notes:

(a) The number and percentage of votes are based on the total number of shares of the Company voted by the shareholders of the Company at the AGM in person or by proxy.

(b) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 6 above, all resolutions were duly passed as ordinary resolutions.

(c) The total number of shares of the Company in issue as at the date of AGM is 572,402,000 Shares, which is the total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM.

(d) As at the date of the AGM, there were (i) no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and therefore, no voting rights of treasury shares were exercised at the AGM; and (ii) no repurchased shares which were to be cancelled and shall be excluded from the total number of issued shares entitling the holders to attend and vote on the resolution proposed at the AGM.

(e) There were no shares of the Company entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM (as set out in Rule 13.40 of the Listing Rules).

(f) No shareholder of the Company was required under the Listing Rules to abstain from voting at the AGM.

(g) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

(h) The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

(i) All Directors attended the AGM by means of electronic communication.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, June 2, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive Directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive Directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive Directors.